A biotech firm, OncoTrap is structured around addressing the development to use-condition of medications that activate or enhance the immune response to remove the burden of tumors. Principals of the firm are indicated as working on in-vivo nucleic delivery and de-novo protein engineering technologies, which would allow healthcare providers to deliver therapeutic genes to tumor sites. Anchored in identifying drug target binding molecules using in vitro protein selection and protein engineering, the approach of ine of using affinity molecules to trap the immuno-suppressive signals in the microenvironment of diseased tissues to treat solid tumors and autoimmune diseases. The product pipeline includes OT-1, a therapy that targets the chemokine protein CXCL12 to treat pancreatic ductal adenocarcinoma; OT-2, which targets programmed cell death protein 1 (PD1) in pancreatic cancers; OT-3, which traps a cytokine in tumor sites; and OT-4, a polymer-based self-assembly system that is designed to deliver siRNA against Kras mutant (G12D) to cancer cells.
